The European Medicine Agency (EMA) has recommended a change to marketing authorization for encorafenib and binimetinib for the treatment of adults with non-small cell lung cancer. These drugs, when used in combination, as well as the drug cetuximab, may also be used to treat metastatic melanoma and metastatic colorectal cancer.
To learn more about this recommendation, click here.
No comments:
Post a Comment